Can I Switch My Kidney Transplant Patient from Tacrolimus to Belatacept?
A recent study by Grinyó et al published in AJKD reveal the three year results of a multicenter randomized controlled phase II trial where stable kidney transplant [...]
Nair
#ATC2016Boston: Novel Immunosuppressants
One of the ATC concurrent sessions was dedicated to novel immunosuppressants. Here is a brief breakdown of the session. Dr. Muhbacher presented Phase 1 results of a novel [...]
#ATC2016Boston: Updates on Kidney Allocation
The new kidney allocation system (KAS) began December 2014. As previously blogged, key strategic goals of the KAS include more equity for highly sensitized patients, [...]
#ATC2016Boston: Desensitization
Highly sensitized patients are among the most difficult to transplant and are plagued by early rejection and graft loss. Currently, most immunosuppressive agents are [...]
#ATC2016Boston: Does using Everolimus instead of Tacrolimus reduce CKD after liver transplantation?
The investigators of the SIMCER study set out to answer this very question. The incidence of stage 4 CKD 5 years after kidney transplant ranges from 7-21%. Up to 60% of [...]
#ATC2016Boston: HVC-Infected Kidney Transplant Recipients
The American Transplant Congress (ATC) is the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. This year [...]
LCP-Tacrolimus: A Novel Extended-Release Tacrolimus for Use in Kidney Transplantation
Tacrolimus is the cornerstone of immunosuppression in solid organ transplantation. The SRTR annual data report from 2014 suggests that > 90% of kidney transplant [...]
Paying Kidney Donors — Necessary or Not?
There is a great shortage of transplantable kidneys based on the number of transplant candidates awaiting organs in the United States. Some thought leaders have proposed [...]
Test Your Knowledge: Immunology and Transplantation
AJKD recently published a Core Curriculum by Dr. Donald Hricik on transplant immunology and immunosuppression. The following questions based on the article will test your [...]
ATC2015: Belatacept in Kidney Transplantation
There were several abstracts presented about outcomes in patients treated with belatacept, a recently FDA-approved immunosuppressive agent that blocks T-cell activation. [...]